![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
SP-002 is a biologic therapeutic based on an adenovirus, that has been engineered to produce the immunostimulatory anti-cancer protein, Interferon-g. It is being investigated in combination with vismodegib for treating locally advanced and metastatic basal cell carcinoma.
Lead Product(s): SP-002,Vismodegib
Therapeutic Area: Oncology Product Name: SP-002
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2024